New immunosuppressive strategies in renal transplant recipients

被引：0

作者：

Fischereder, M ^{[1
]}

Kretzler, M ^{[1
]}

机构：

[1] Univ Munich, Med Poliklin Innenstadt, Nephrol Zentrum, D-80336 Munich, Germany

来源：

JOURNAL OF NEPHROLOGY | 2004年 / 17卷 / 01期

关键词：

renal transplantation; cyclosporine; tacrolimus; mycophenolate; leflunomide; sirolimus; chemotaxis; tolerance;

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Along with expanded knowledge of pathophysiological processes involved in transplant rejection, a variety of inummosuppressive agents with very specific modes of action have been developed. The focus of this review is an update on the pathophysiologic rationale and experience with such agents in human renal transplantation that are currently clinically available or are under investigation in human trials. Clinical data are reviewed with respect to calcineurin inhibitor sparing regimens based on mycophenolate or sirolimus, the use of leflunomide and its derivative FK778, modulation of chemotaxis with FTY720 or chemokine receptor blockers and the results of costimulatory blockade. While selection of one of these strategies may allow a more individualised therapy, the inummosuppressive potential of each compound has to be weighed against adverse reactions for an individual patient.

引用

页码：9 / 18

页数：10

共 89 条

[1] Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study [J].

Abramowicz, D ;

Manas, D ;

Lao, M ;

Vanrenterghem, Y ;

del Castillo, D ;

Wijngaard, P ;

Fung, S .

TRANSPLANTATION, 2002, 74 (12) :1725-1734

[2] A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation [J].

Anders, HJ ;

Vielhauer, V ;

Frink, M ;

Linde, Y ;

Cohen, CD ;

Blattner, SM ;

Kretzler, M ;

Strutz, F ;

Mack, M ;

Gröne, HJ ;

Onuffer, J ;

Horuk, R ;

Nelson, PJ ;

Schlöndorff, D .

JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (02) :251-259

[3]

BIRKELAND SA, 1985, TRANSPLANTATION, V39, P677

[4] Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model [J].

Blum, CB .

AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (06) :551-559

[5] The immune modulator FTY720 targets sphingosine 1-phosphate receptors [J].

Brinkmann, V ;

Davis, MD ;

Heise, CE ;

Albert, R ;

Cottens, S ;

Hof, R ;

Bruns, C ;

Prieschl, E ;

Baumruker, T ;

Hiestand, P ;

Foster, CA ;

Zollinger, M ;

Lynch, KR .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21453-21457

[6]

Budde K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341073

[7]

CAMPISTOL JM, 2003, NEPHROL DIAL TRAN S4, V18, pS784

[8]

Chiba K, 1998, J IMMUNOL, V160, P5037

[9] Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients [J].

Citterlo, F ;

Scatà, MC ;

Violi, P ;

Romagnoli, J ;

Pozzetto, U ;

Nanni, G ;

Castagneto, M .

TRANSPLANTATION PROCEEDINGS, 2003, 35 (04) :1292-1294

[10] Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts [J].

Dambrin, C ;

Klupp, J ;

Bîrsan, T ;

Luna, J ;

Suzuki, T ;

Lam, T ;

Stähr, P ;

Hausen, B ;

Christians, U ;

Fitzgerald, P ;

Berry, G ;

Morris, R .

CIRCULATION, 2003, 107 (18) :2369-2374

← 1 2 3 4 5 6 7 8 9 →